Loading...
InVivo Therapeutics Holdings Corporation
NVIV•NASDAQ
HealthcareBiotechnology
$0.32
$-0.17(-34.28%)
InVivo Therapeutics Holdings Corporation (NVIV) Stock Overview
Explore InVivo Therapeutics Holdings Corporation’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for NVIVStats details for NVIV are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for NVIVAnalyst Recommendations details for NVIV are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord to treat acute SCI. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts.
CEO
Dr. Richard M. Toselli M.D.
Employees
6
Headquarters
One Kendall Square, Cambridge, MA
Founded
2010